Oxidation of dihydropyridine calcium channel blockers and analogs by human liver cytochrome P-450 IIIA4
摘要:
A series of 21 different 4-substituted 2,6-dimethyl-3-(alkoxycarbonyl)-1,4-dihydropyridines was considered with regard to oxidation to pyridine derivatives by human liver microsomal cytochrome P-450 (P-450). Antibodies raised against P-450 IIIA4 inhibited the microsomal oxidation of nifedipine and felodipine to the same extent, as did cimetidine and the mechanism-based inactivator gestodene. Gestodene was approximately 10(3) times more effective an inhibitor than cimetidine, on a molar basis. When rates of oxidation of the 1,4-dihydropyridines were compared to each other in different human liver microsomal preparations, all were highly correlated with each other with the exceptions of a derivative devoid of a substituent at the 4-position and an N1-CH3 derivative. A P-4.50 IIIA4 cDNA clone was expressed in yeast and the partially purified protein was used in reconstituted systems containing NADPH-cytochrome P-450 reductase and cytochrome b5. This system catalyzed the oxidation of all of the 1,4-dihydropyridines except the two for which poor correlation was seen in the liver microsomes. Principal component analysis supported the view that most of these reactions were catalyzed by the same enzyme in the yeast P-450 IIIA4 preparation and in the different human liver microsomal preparations, or by a closely related enzyme showing nearly identical properties of catalytic specificity and regulation. The results indicate that the enzyme P-450 IIIA4 is probably the major human catalyst involved in the formal dehydrogenation of most but not all 1,4-dihydropyridine drugs.
[EN] MINERALOCORTICOID RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS MINÉRALOCORTICOÏDES
申请人:MERCK & CO INC
公开号:WO2009078934A1
公开(公告)日:2009-06-25
The present invention relates to dihydropyridine mineralcorticoid receptor modulating compounds having the structure: and their use in treating cardiovascular events.
used as substrates to obtain chiral Hantzsch-type 1,4-DHPs, which are frequently contained in pharmaceuticals. The inert C−H bond was converted into a versatile C−Br bond, which enabled the modification of the chiral 1,4-DHP derivatives with high efficiency by nucleophilic substitution. Furthermore, axially chiral 4-aryl pyridines were accessible by central-to-axial chirality conversion.
The present invention relates to dihydropyridine mineralocorticoid receptor modulating compounds having the structure: and their use in treating cardiovascular events.
Photoinduced Electron and Energy Transfer in Aryldihydropyridines
作者:Angel J. Jimenez、Maurizio Fagnoni、Mariella Mella、Angelo Albini
DOI:10.1021/jo9010816
日期:2009.9.4
Dimethyl 2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylates (Hantzsch DHPs) fluoresce weakly in fluid solution. However, these compounds exhibit an efficient fluorescence both in a viscous medium (glycerin) at room temperature and in a glassy matrix at 77 K (but no phosphorescence, since ISC is negligible). DHPs bearing an aryl roup in position 4 have been synthesized. These contain two different pi systems separated by an sp(3) carbon (DHP-Ar dyads). The occurrence of energy and electron transfer processes between the chromophores is investigated through luminescence measurements. In particular, when Ar-3 emits at a slow rate (e.g., Ar = phenanthryl) or not at all (Ar = nitrophenyl) the intradyad forward/backward electron transfer sequence offers a path for arriving at the DHP-localized triplet and the corresponding phosphorescence is observed. When Ar-3 emits at a faster rate (Ar = acylphenyl), the phosphorescence from either of the two localized triplets, Ar-3 or (DHP)-D-3, can be observed depending on lambda(exc.) When the aryl group has a triplet energy lower than that of (DHP)-D-3, this functions as emitting (4-cyano-l-naphthyl) or nonemitting (MeO2CCH=CHC6H4) energy sink. The results document the possibility of building tailor-made Hantzsch aryldihydropyridines as versatile photoactivated dyads.